Risk survey of large pharmaceutical plants

CEERISK was instructed to conduct a risk engineering survey of a large pharmaceutical manufacturing plants. The plant is owned and operated by a leading biopharmaceutical corporation dedicated to developing, manufacturing and commercialising quality branded generic medications. These medications improve health outcomes, cost of care and the wellbeing of patients across the Middle East and Africa (MEA) region. With our unique approach to identifying, assessing and analysing insurable risks, we were able to develop a list of recommendations that assisted both the insured and the insurers in implementing a number of steps that enhanced the risk profile of plant.